New Hope for Treatment-Resistant Schizophrenia Revealed at Newron Pharmaceuticals 2024 Investor Day
Newron Pharmaceuticals S.p.A. announced its upcoming 2024 Investor Day on June 25, 2024, in New York City. The event will focus on the Company’s plans for evenamide for chronic and treatment-resistant schizophrenia, shedding light on the latest breakthroughs in neurobiology for poorly responding patients.
Leading experts in neuroscience and schizophrenia, including Anthony Grace, John Kane, and Stephen Marder, will present cutting-edge pre-clinical data and discuss the unique efficacy of evenamide in targeting the site of pathology in schizophrenia patients. This event aims to address the unmet needs and provide new hope for those struggling with treatment-resistant schizophrenia.
Evenamide, a promising new chemical entity, shows potential in normalizing glutamate release and offering synergistic benefits when combined with other antipsychotic medications. The Company’s commitment to advancing novel therapies for CNS diseases underscores the importance of exploring innovative treatment options for patients in need.
Newron Pharmaceuticals continues to pave the way in developing groundbreaking therapies for central and peripheral nervous system disorders. The 2024 Investor Day serves as a platform to engage with stakeholders, share research progress, and reinforce the Company’s dedication to improving patient outcomes.
As the landscape of schizophrenia treatment evolves, the revelations from Newron Pharmaceuticals’ Investor Day offer a glimpse of hope for individuals battling treatment-resistant schizophrenia. Stay tuned for further updates on the transformative potential of evenamide in revolutionizing the treatment paradigm for this challenging condition.
